Lamm S H
Consultants in Epidemiology and Occupational Health, Inc., Washington, DC, USA.
J Clin Epidemiol. 1995 Apr;48(4):507-11. doi: 10.1016/0895-4356(94)00206-6.
The epidemiological literature examining the possible association between silicone breast implants and breast cancer or rheumatological conditions or diseases is far greater today than it was when, in early 1992, FDA determined that the data were not adequate for the assessment of their safety. A literature data base exists for assessing the magnitude of risk for certain diseases that might be associated with silicone breast implantation and for narrowing the uncertainty in those estimates. The studies reported in this series make a major contribution to that database. As for future research needs, some general observations can be made. First, it is likely that completed, ongoing and planned studies will prove more than adequate in accurately delineating any cancer risks that might be associated with breast implantation. Second, the risks of developing scleroderma will also be reasonably well established. Further study may be desirable for other specific connective tissue diseases and for connective tissue disease considered as a whole.
如今，与1992年初美国食品药品监督管理局（FDA）认定数据不足以评估硅胶乳房植入物安全性时相比，探讨硅胶乳房植入物与乳腺癌、风湿性疾病或病症之间可能存在关联的流行病学文献要多得多。现有一个文献数据库，用于评估某些可能与硅胶乳房植入相关疾病的风险程度，并缩小这些评估中的不确定性。本系列报道的研究对该数据库做出了重大贡献。至于未来的研究需求，可以提出一些一般性看法。首先，已完成、正在进行和计划中的研究很可能足以准确描述与乳房植入相关的任何癌症风险。其次，患硬皮病的风险也将得到合理的确立。对于其他特定的结缔组织疾病以及整体上的结缔组织疾病，可能需要进一步研究。
